AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27981462 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational leaflet about psoriatic arthritis (PsA)
Number of subjects: 191
Study 27981462 — intervention group
Group type: COMPARATOR
Intervention: Study information alone (Control)
Number of subjects: 191
Study 26071920 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for mild GDM
Number of subjects: 958
Study 23433504 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU intranasal)
Number of subjects: 35
Study 23433504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 21969851 — intervention group
Group type: EXPERIMENTAL
Intervention: UC781 gel 0.25%
Number of subjects: 36
Study 21969851 — intervention group
Group type: EXPERIMENTAL
Intervention: UC781 gel 0.1%
Number of subjects: 36
Study 21969851 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 36
Study 19725440 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential-guided approach
Number of subjects: 228
Study 19725440 — intervention group
Group type: COMPARATOR
Intervention: Anatomic-guided approach
Number of subjects: 228
Study 17597643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactobacillus casei (100 mL, 10^8 cfu/mL)
Number of subjects: 187
Study 17597643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 15173473 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group (N = 42)
Number of subjects: 89
Study 15173473 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 47)
Number of subjects: 89
Study 15173473 — intervention group
Group type: COMPARATOR
Intervention: Control group with vitamin E deficiency (alpha-T < 300 microg/dl)
Number of subjects: 89
Study 15173473 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 89
Study 15173473 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low plasma alpha-tocopherol levels at diagnosis
Number of subjects: 89
Study 11432470 — intervention group
Group type: COMPARATOR
Intervention: Standard uncoated ECC with systemic heparin 400 IE/kg
Number of subjects: 243
Study 11432470 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated ECC with systemic heparin 400 IE/kg
Number of subjects: 243
Study 11432470 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated ECC with reduced systemic heparin 150 IE/kg
Number of subjects: 243
Study 9821850 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg
Number of subjects: 50
Study 9821850 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine 20 mg
Number of subjects: 50
Study 7523271 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 8
Study 2557274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2 puffs of 2 mg each twice daily)
Number of subjects: 131
Study 2557274 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 puffs twice daily)
Number of subjects: 131
Study 31280694 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-sensitive pain neuroscience education (PNE)
Number of subjects: 29
Study 31280694 — intervention group
Group type: COMPARATOR
Intervention: Standard pain neuroscience education (PNE)
Number of subjects: 29
Study 31096828 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin graft technique
Number of subjects: 14
Study 31096828 — intervention group
Group type: COMPARATOR
Intervention: Graftless technique
Number of subjects: 14
Study 29423885 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation of the basivertebral nerve (BVN)
Number of subjects: 225
Study 29423885 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 225
Study 27278517 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate catheter stability VisiTag setting (3-mm distance limit for at least 5 s, minimum contact force of 8 g over 25% of the set time period, target FTI ≥300 g*s)
Number of subjects: 54
Study 27278517 — intervention group
Group type: COMPARATOR
Intervention: Strict catheter stability VisiTag setting (3-mm distance limit for at least 10 s, minimum contact force of 10 g over 50% of the set time period, target FTI ≥400 g*s)
Number of subjects: 54
Study 27278517 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Moderate and Strict catheter stability settings)
Number of subjects: 54
Study 24781054 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with SSRIs (Selective Serotonin Reuptake Inhibitors)
Number of subjects: 76
Study 24781054 — intervention group
Group type: COMPARATOR
Intervention: SSRIs only (Control Group)
Number of subjects: 76
Study 22092915 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve M‐16V combined with a prebiotic oligosaccharide mixture (synbiotic)
Number of subjects: 90
Study 22092915 — intervention group
Group type: COMPARATOR
Intervention: Placebo (infant formula without synbiotics)
Number of subjects: 90
Study 20231786 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta 1B (IFNB 1b)
Number of subjects: 32
Study 20231786 — intervention group
Group type: COMPARATOR
Intervention: Control group (not taking IFNB 1b)
Number of subjects: 32
Study 20231786 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IFNB 1b and control)
Number of subjects: 32
Study 18605602 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR) with anorganic bovine bone and resorbable collagen membrane
Number of subjects: 34
Study 18605602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no grafts or membranes)
Number of subjects: 34
Study 15855243 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose 24%
Number of subjects: 23
Study 15855243 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 23
Study 11478144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron hydrochloride (OND group)
Number of subjects: 78
Study 11478144 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent use of ondansetron and dexamethasone (DEX group)
Number of subjects: 78
Study 11478144 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (part of DEX group)
Number of subjects: 78
Study 9203804 — intervention group
Group type: EXPERIMENTAL
Intervention: O2 night (LTOT)
Number of subjects: 16
Study 9203804 — intervention group
Group type: COMPARATOR
Intervention: Air night (room air)
Number of subjects: 16
Study 8424733 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg scopolamine
Number of subjects: 60
Study 8424733 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg methscopolamine
Number of subjects: 60
Study 8424733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3301606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride, 10 mg three times daily, orally, before meals
Number of subjects: 18
Study 3301606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3301606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 18
Study 2806497 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of cold dry air for 2 minutes
Number of subjects: 12
Study 2806497 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of cold dry air for 3 minutes
Number of subjects: 12
Study 2806497 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of cold dry air for 4 minutes
Number of subjects: 12
Study 30686542 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate Dialysis Fluid (CDF) with 1mmol/L of citrate
Number of subjects: 56
Study 30686542 — intervention group
Group type: COMPARATOR
Intervention: Acetate Dialysis Fluid (ADF) with 3mmol/L of acetate
Number of subjects: 56
Study 30686542 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate Dialysis Fluid (CDF)
Number of subjects: 56
Study 30686542 — intervention group
Group type: COMPARATOR
Intervention: Acetate Dialysis Fluid (ADF)
Number of subjects: 56
Study 28800398 — intervention group
Group type: EXPERIMENTAL
Intervention: PROG (lifestyle modification program with targeted nutraceutical supplementation)
Number of subjects: 44
Study 28800398 — intervention group
Group type: EXPERIMENTAL
Intervention: PROG
Number of subjects: 44
Study 28800398 — intervention group
Group type: COMPARATOR
Intervention: DIET (lifestyle modification program without nutraceutical supplementation)
Number of subjects: 44
Study 25434500 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of tramadol intramuscularly (group T; n = 29)
Number of subjects: 60
Study 25434500 — intervention group
Group type: COMPARATOR
Intervention: 1 g of paracetamol intravenously (group P; n = 30)
Number of subjects: 60
Study 24296481 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation (8 weeks, 3 to 5 sessions per week, minimum of 1 supervised session)
Number of subjects: 128
Study 21502222 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive stimulation and feeding intervention (6 sessions with peer educators)
Number of subjects: 302
Study 21502222 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive stimulation and feeding intervention with micronutrient fortification (6 sessions + 6 months of fortified food powder)
Number of subjects: 302
Study 21502222 — intervention group
Group type: COMPARATOR
Intervention: Regular information-based parenting program (12 informational sessions on health and nutrition)
Number of subjects: 302
Study 19374960 — intervention group
Group type: EXPERIMENTAL
Intervention: Short waiting time (<=3 months)
Number of subjects: 309
Study 19374960 — intervention group
Group type: COMPARATOR
Intervention: Non-fixed waiting time (>3 months)
Number of subjects: 309
Study 16740859 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician Asthma Care Education program
Number of subjects: 870
Study 16249508 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled carbon monoxide (500 ppm)
Number of subjects: 15
Study 16249508 — intervention group
Group type: COMPARATOR
Intervention: Placebo (synthetic air without CO)
Number of subjects: 15
Study 11565320 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 11565320 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 0
Study 9627524 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg
Number of subjects: 89
Study 9627524 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg
Number of subjects: 89
Study 9627524 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 89
Study 9627524 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 89
Study 9627524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg
Number of subjects: 89
Study 9627524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg
Number of subjects: 89
Study 7933821 — intervention group
Group type: EXPERIMENTAL
Intervention: Human atrial natriuretic peptide (ANP) at 0.20 micrograms/kg/min i.v. for 24 hours or 0.08 micrograms/kg/min i.a. for 8 hours, with furosemide or mannitol or no diuretic.
Number of subjects: 53
Study 7933821 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group II) treated with diuretics or no diuretic, without ANP.
Number of subjects: 53
Study 3065976 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 19
Study 3065976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31140342 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation antipsychotics in patients with substance use
Number of subjects: 226
Study 31140342 — intervention group
Group type: COMPARATOR
Intervention: Second generation antipsychotics in patients without substance use
Number of subjects: 226
Study 31140342 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 226
Study 29048352 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS) in fermented milk (6.5 × 10⁸ cfu) daily for 8 weeks
Number of subjects: 60
Study 26160525 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg t.i.d. for 1 month
Number of subjects: 13
Study 26160525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 23307258 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOT regimen (oxaliplatin 85 mg/m², docetaxel 50 mg/m², leucovorin 200 mg/m², 5-FU 1200 mg/m²) administered biweekly
Number of subjects: 50
Study 23307258 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOT regimen
Number of subjects: 50
Study 21217084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m(2) weekly × nine cycles
Number of subjects: 285
Study 21217084 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m(2) every 21 days × six cycles (Control)
Number of subjects: 285
Study 19080741 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment comprising luteinizing hormone-releasing hormone (LH-RH) agonists and tamoxifen
Number of subjects: 0
Study 19080741 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 0
Study 19080741 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors coupled with LH-RH agonists
Number of subjects: 0
Study 17160909 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 17160909 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (rosiglitazone, pioglitazone)
Number of subjects: 0
Study 17160909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylureas
Number of subjects: 0
Study 14533658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 88 microg and salmeterol 42 microg (FSC) in a CFC-free MDI
Number of subjects: 283
Study 14533658 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 88 microg (FP) in a CFC-containing MDI
Number of subjects: 283
Study 14533658 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 42 microg in a CFC-containing MDI
Number of subjects: 283
Study 11302273 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention group
Number of subjects: 66
Study 11302273 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 66
Study 9399371 — intervention group
Group type: EXPERIMENTAL
Intervention: Food deprivation
Number of subjects: 82
Study 9399371 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive motivation
Number of subjects: 82
Study 9399371 — intervention group
Group type: COMPARATOR
Intervention: Control (no food deprivation)
Number of subjects: 82
Study 8309607 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg/4 hours i.v. during the first 24 hours, 2 mg/6 hours during the following 24 hours)
Number of subjects: 30
Study 8309607 — intervention group
Group type: COMPARATOR
Intervention: Octreotide (50 micrograms i.v. followed by 25 micrograms/hour infusion)
Number of subjects: 30
Study 3103764 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 211
Study 3103764 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder drill
Number of subjects: 211
Study 3103764 — intervention group
Group type: EXPERIMENTAL
Intervention: Propantheline
Number of subjects: 211
Study 3103764 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 211
Study 30061194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1021
Study 27422625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 0
Study 27422625 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 25409020 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio supplementation (3 oz./d for 2 weeks)
Number of subjects: 19
Study 25409020 — intervention group
Group type: COMPARATOR
Intervention: No pistachio supplementation (control)
Number of subjects: 19
Study 22959217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) 120 mg twice per day
Number of subjects: 2854
Study 22959217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2854
Study 22959217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761)
Number of subjects: 2854
Study 20534062 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey supplementation
Number of subjects: 30
Study 20534062 — intervention group
Group type: COMPARATOR
Intervention: Conventional nutritional rehabilitation therapy
Number of subjects: 30
Study 18198649 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention enema with combination of Chinese and Western drugs
Number of subjects: 0
Study 18198649 — intervention group
Group type: COMPARATOR
Intervention: Western drugs alone
Number of subjects: 0
Study 15613587 — intervention group
Group type: EXPERIMENTAL
Intervention: Applying the sensor to the infant before connecting to the oximeter
Number of subjects: 0
Study 15613587 — intervention group
Group type: COMPARATOR
Intervention: Control method not specified
Number of subjects: 0
Study 11881888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (5 mg kg(‐1))
Number of subjects: 98
Study 11881888 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (0.625 mg kg(‐1))
Number of subjects: 98
Study 11881888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 10221802 — intervention group
Group type: EXPERIMENTAL
Intervention: Full chart visual acuity test
Number of subjects: 75
Study 10221802 — intervention group
Group type: EXPERIMENTAL
Intervention: Single line visual acuity test
Number of subjects: 75
Study 10221802 — intervention group
Group type: EXPERIMENTAL
Intervention: Single optotype visual acuity test
Number of subjects: 75
Study 10221802 — intervention group
Group type: COMPARATOR
Intervention: Control group (ophthalmologically normal children)
Number of subjects: 75
Study 7894298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glucagon
Number of subjects: 0
Study 7894298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucagon
Number of subjects: 0
Study 7894298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2505698 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibronectin (Fn)
Number of subjects: 85
Study 2505698 — intervention group
Group type: COMPARATOR
Intervention: Human serum albumin (HSA)
Number of subjects: 85
Study 2505698 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 85
Study 335196 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 60
Study 335196 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 60
Study 31969369 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice
Number of subjects: 160
Study 31969369 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-deplete beetroot juice (placebo)
Number of subjects: 160
Study 31784567 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus (RSV) testing
Number of subjects: 2385
Study 31784567 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical simulation for expected incidence of ALRI
Number of subjects: 2385
Study 31784567 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of ALRI cases due to RSV vs PIV or IV
Number of subjects: 2385
Study 27671119 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/AIDS education
Number of subjects: 0
Study 27671119 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/AIDS education + home‐based VCT
Number of subjects: 0
Study 27671119 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/AIDS education + CCT for facility‐based VCT
Number of subjects: 0
Study 27671119 — intervention group
Group type: EXPERIMENTAL
Intervention: home‐based VCT
Number of subjects: 0
Study 27671119 — intervention group
Group type: COMPARATOR
Intervention: CCT for facility‐based VCT
Number of subjects: 0
Study 27233921 — intervention group
Group type: EXPERIMENTAL
Intervention: Calanus oil (2 g daily for one year)
Number of subjects: 64
Study 27233921 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 64
Study 24702797 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer adherence support (PAS) intervention
Number of subjects: 0
Study 24702797 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer adherence support (PAS) intervention with nutritional support
Number of subjects: 0
Study 24702797 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 22510791 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1400 IU weekly from birth to 6 months)
Number of subjects: 0
Study 22510791 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 0
Study 20538398 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvinylpyrrolidone sodium hyaluronate gel (Aloclair) 3 times daily for 1 week
Number of subjects: 90
Study 20538398 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate gel 3 times daily for 1 week
Number of subjects: 90
Study 20538398 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study 18525382 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise capacity over 230 W
Number of subjects: 1639
Study 18525382 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise workload (for 20 W increment)
Number of subjects: 1639
Study 18525382 — intervention group
Group type: EXPERIMENTAL
Intervention: European SCORE (for 1% increment)
Number of subjects: 1639
Study 16198768 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-month interferon alfa 2b treatment (10 MU 5 days a week for 4 weeks, then 10 MU three times a week for 1 year)
Number of subjects: 1388
Study 16198768 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-month interferon alfa 2b treatment (10 MU 5 days a week for 4 weeks, then 5 MU three times a week for 2 years)
Number of subjects: 1388
Study 16198768 — intervention group
Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 1388
Study 12357302 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (80 mg/m²) administered after fasting
Number of subjects: 18
Study 12357302 — intervention group
Group type: COMPARATOR
Intervention: Oral vinorelbine (80 mg/m²) administered after ingestion of a standard continental breakfast
Number of subjects: 18